Dr. Nagi S. El Saghir, Director at NKBCI in Beirut, highlights six key abstracts from SABCS 2024. He shares insights on the rich multidisciplinary data presented this year, spanning innovations in breast cancer research and treatment.
Dr. Antonio Wolff shares expert commentary on SABCS 2024 highlights, including the practice-changing PATINA study, DCIS data, the COMET study, and the FDA's discussion on the importance of ovarian toxicity monitoring during clinical trials.
Prof. Amelie Ramirez discusses the importance of advancing research in prevention and treatment adherence for underserved Hispanic populations. She emphasizes clinical trial access and tailored treatments to combat breast cancer, a leading cause of death in this community.
Dr. Rita Sakr, Head of Breast Surgery at Emirates Hospital Dubai, discusses breast cancer survivors’ perspectives on de-escalation treatments in the Arab world and emphasizes the importance of education and raising awareness on de-escalation protocols.
Dr. Aydah AlAwadhi from the UAE shares insights on obesity's impact on breast cancer prevention, risk reduction, and prognosis, with key takeaways from Dr. H. Pan's (EBCTCG) presentation. She emphasizes the critical need for education and strategies to combat obesity in breast cancer patients.
Barbara Segarra-Vazquez, patient advocate and 2x breast cancer survivor, highlights drug optimization at SABCS 2024, emphasizing initiatives like Project Optimus and the importance of flexible dosing to enhance patients’ quality of life.
Prof. Amelie Ramirez reflects on SABCS 2024, highlighting advances from prevention to survivorship, the vital role of patient advocates in guiding research, and how new discoveries are improving the lives of breast cancer survivors.
Prof. Rebecca Dent discusses defining TNBC and shares updates from the KEYNOTE-522 study on neoadjuvant pembrolizumab for high-risk, early-stage TNBC. A detailed review of the progress and insights shaping TNBC management today.
Dr. Saima Hassan, Surgical Oncologist at the CHUM in Montreal and co-author of the B-59/GeparDouze study, emphasizes Quebec's role, contributing 17% of patients. She discusses the study's findings, its implications, and the need for further biomarker exploration.
Dr. Paolo Tarantino reviews two practice-changing trials presented at SABCS, EMBER-3 and PATINA. He discusses his own presentation on real-world data and innovative biomarkers for optimizing ADC use in breast oncology.
Dr. Joseph Gligorov discusses the pivotal PATINA trial results, emphasizing its significance as one of the most important data sets presented at SABCS 2024, with implications for advancing treatment in metastatic breast cancer.
On SABCS 2024's final day, Dr. Jean-Pierre Ayoub discusses three key abstracts, including NSABP B-59/GBG-96-GeparDouze on immunotherapy in TNBC and a subgroup analysis of TAILORx exploring chemotherapy variations. Valuable insights shared!
Dr. Jean-Pierre Ayoub discusses the evolving field of ADCs in Canada, comments on additional analysis from DESTINY-Breast06 by Dr. Aditya Bardia, and explores the expanding indications for trastuzumab deruxtecan (T-DXd).
Dr. Lisa Carey highlights the practice-changing PATINA trial, a mature study addressing the critical question of whether CDK4/6 inhibitors improve outcomes when added to antiestrogen and anti-HER2 therapies in first-line treatment of metastatic HR+/HER2+ breast cancer.
Dr. Xiaofu Zhu provides key takeaways from important abstracts at SABCS, including the EMBER-3 study, the exciting phase 2 SOLTI VALENTINE study, and highlights from several de-escalation studies.
Dr. Mitchell Elliott presents his spotlight poster on Day 3, evaluating the Pathlight Assay, a new ultra-sensitive ctDNA assay, in the early breast cancer setting. Discover the potential of this innovative diagnostic tool.
Dr. Jean-Pierre Ayoub shares insights on the DESTINY-Breast12 trial, highlighting the reassuring effects of T-DXd on quality of life and neurological function in HER2+ metastatic breast cancer patients, with or without brain metastases.
On Day 3, Dr. Stephanie Wong discussed the exciting results of the INSEMA trial, the second study showing that sentinel lymph node biopsy can be successfully omitted. We're eagerly awaiting further details to see if this approach can be widely implemented in practice.
Day 3 of SABCS 2024 reviewed by Drs. Sideris, Ayoub, and guest Dr. Ipshita Prakash, covering results from EUROPA, COMET, INSEMA, and PATINA trials. Key themes: de-escalation in treatment and a patient-centered care approach.
Dr. Kevin Kalinsky explores the impact of omitting axillary staging on adjuvant therapy in ER+ breast cancer. From SABCS' clinical controversy session, discover 4 key insights on systemic therapy implications.
Join Dr. Aditya Bardia as he explores the efficacy and safety of trastuzumab deruxtecan (T-DXd) vs. physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy in the latest DESTINY-Breast06 analysis.
Drs Lucas Sideris, Jean-Pierre Ayoub, and guest Cristiano Ferrario discuss Day 2 highlights including metastatic and early breast cancer updates, PADMA and EMBER-3 results, PRO B study insights, OlympiA follow-up, and what to expect on Day 3
Dr. Jane Meisel discusses key Day 2 updates from SABCS, including Dr. Matteo Lambertini's study on risk-reducing surgeries and survival in young BRCA carriers and the OlympiA Phase 3 10-year follow-up. These findings underscore advances and the importance of BRCA testing in early breast cancer.
Dr. Marie-France Jilderda discusses findings on the Adjusted Breast Cancer Index Model, exploring its role in identifying HR+ breast cancer patients at minimal 10-year distant recurrence risk and the key rationale behind this critical investigation.
Join Dr. Asselah and Dr. Sidéris as they review Day 1 of SABCS 2024, discussing late-breaking abstracts, key updates, and whether this year's findings could bring practice-changing advancements in breast cancer care.
Dr. Edith A. Perez, Professor Emeritus at Mayo Clinic, Chief Scientific Officer at oncoXchange, and an internationally recognized translational researcher and cancer specialist, previews SABCS 2024. She shares insights on the most anticipated abstracts and studies, highlighting exciting and potentially practice-changing results that could shape the future of breast cancer care.
Dr. Tarek Hijal provides key insights from Day 3 of ESMO 2024, focusing on the latest developments in hypofractionated radiotherapy for breast cancer. He discusses significant findings from the Phase III HypoG-01 trial, led by Dr. Sofia Rivera from Gustave Roussy, France. Dr. Hijal explores how these results are poised to impact breast cancer treatment, particularly in optimizing radiotherapy approaches for better patient outcomes.
Watch as Prof. Sibylle Loibl, PI of the PENELOPE-B trial, presents the final overall survival and subgroup analyses for lobular breast cancer patients at ESMO 2024. Gain a detailed overview of the study's key findings and implications.
Dr. Jamil Asselah, along with guests Dr. Kim Ma and Dr. Paolo Tarantino, discuss the morning sessions focused on metastatic and early breast cancer. The panel recaps significant data including insights from the DETECT V trial, KEYNOTE 522, DESTINY-Breast12, and updates from the Natalee trial.
Dr. Jean-Philippe Spano provides a brief history of ESMO's origins and its remarkable growth over the years. He reviews the latest data presented, with a special focus on contributions from his French colleagues and key international studies that have shaped clinical practice in breast cancer oncology.
Dr. Cristina Saura highlights three key messages from the ESMO 2024 meeting, focusing on significant advancements in breast cancer research. First, the results of the DESTINY-Breast12 trial showcased new treatment options for advanced breast cancer. Second, the ICARUS-BREAST01 study provided further insights into innovative therapeutic approaches. Lastly, she emphasized two groundbreaking international studies that confirmed breastfeeding after breast cancer treatment does not increase the risk of recurrence or new cancers, marking an important step for young survivors seeking safe breastfeeding options.
In this video,Dr. Amy Abernethy highlights the transformative potential of AI in oncology and stresses the need for safety and efficacy in patient care. She outlines three key trends essential for scaling AI in the field.
In this video, Dr. Erika Hamilton highlights the latest data on trastuzumab and HER2 testing presented at ESMO 2024. She provides valuable insights into recent advancements and their implications for treatment strategies in HER2-positive cancers.
In this DailyRECAP for September 15th, Dr. Jamil Asselah returns for a second overview of the day’s breast cancer sessions from ESMO 2024, joined by Dr. Rami Younan and Dr. Kim Ma. They focus on key insights from the Presidential Symposium and practice-changing trials.
Dr. Barbara Pistilli, Head of the Breast Pathology Committee at Gustave Roussy, presents the promising results of the Phase II ICARUS-BREAST01 trial at ESMO 2024.
Dr. Peter Schmid presents the long-awaited overall survival data for Pembrolizumab in early-stage triple-negative breast cancer. His insights provide a crucial update on the impact of this therapy, highlighting significant advancements in treatment outcomes.
Dr. Javier Cortés, Head of the International Breast Cancer Center in Barcelona, Spain, reviews key insights from the recent ASCO meeting, focusing on the PEARLY trial, A-BRAVE, and I-SPY 2.2 abstracts.
Dr. Erika P. Hamilton shares the findings that bring fantastic news for patients with HER2+ breast cancer, showing an impressive improvement in survival by approximately 10 months.
Explore the findings of the PALMARES-2 study with Dr. Claudio Vernieri, offering crucial real-world insights into the efficacy of CDK4/6 inhibitors. Learn how these insights aid clinicians and patients in making informed treatment decisions for specific clinical settings.
Dr. Dominici Chairs ASCO’s "Breast Cancer Local/Regional/Adjuvant" therapy session where 9 abstracts covered a number of different topics, three of which look at some interesting additions to standard therapy.
Dr. Shaheena Dawood shares her excitement about the wealth of information related to patients with breast cancer and how this data will impact clinical practice. In particular, she highlights three crucial pieces of information from ASCO and reviews data from the DESTINY-Breast06 Update, post MONARCH study and updated analysis from the innovaTV207 trial.
Dr. Maryellen Giger discusses the exciting developments in artificial intelligence (AI) applied to breast cancer imaging. From risk assessment to early detection, diagnosis, prognosis, and treatment response, AI is making significant strides
Join Dr. Stephanie Wong at ASCO as she presents data on PARP inhibitor eligibility in women with newly diagnosed invasive breast cancer. This research is part of the GREAT AGATA Study, a universal genetic testing initiative aimed at improving patient outcomes.
Dr. Judy-Anne Williams Chapman, PhD, emphasizes her four decades of work on the critical topic of estrogen and progesterone receptors. She proposes an adjunctive statistical standardization of quantitated ER and PgR to enhance inter-laboratory comparability of biomarker results and improve the therapeutic management of breast cancer.
Join Dr. Jamil Asselah and Dr. Kim Ma, along with Dr. Véronique Diéras, as they review the day's highlights with a special focus on the positive findings from the DESTINY-Breast06 trial. They will discuss how these results are set to impact clinical practice, particularly for patients with HER2-ultralow breast cancer, and delve into all aspects of T-DXd in treatment strategies.
Join Dr. Jane Lowe Meisel as she presents the first results from the I-SPY2.2 trial at ASCO. This study explores the use of datopotamab deruxtecan as part of neoadjuvant therapy for high-risk, HER2-negative early-stage breast cancer.
Join Dr. Matthew P. Goetz as he discusses the open-label, randomized, multicenter phase 3 ELAINE 3 study. This research investigates the efficacy and safety of lasofoxifene combined with abemaciclib for treating ER+/HER2- locally advanced or metastatic breast cancer with an ESR1 mutation. Discover the potential impact of these findings on patient care and treatment options.
Join Dr. Jean-Pierre Ayoub as he reviews important results from the DESTINY-Breast06 trial. Learn how Trastuzumab Deruxtecan significantly improves progression-free survival in breast cancer patients previously treated with endocrine therapy. Discover the potential implications of these findings for patient care and treatment strategies.
Join Dr. Mark Basik as he presents the results of the TRICIA study, conducted across cancer centers and hospitals in Quebec and Ontario. Learn about the significant findings and the plans to initiate a clinical trial in the coming years, with the goal of advancing treatment options for this challenging type of cancer.
Join Drs. Asselah and Ma as they review the key takeaways from Day 1 of ASCO. They delve into hormone-positive disease, discuss notable abstracts, and provide insights on the Flex trial registry. Hear about Dr. Grace Choong’s research from Mayo Clinic on endocrine therapy for ER-low breast cancer patients. Stay tuned for what to expect in the days ahead at the conference.
Join Dr. Pier Franco Conte as he discusses the A-BRAVE trial, a Phase III randomized study exploring the use of avelumab in early triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy or those at high risk following primary surgery and adjuvant chemotherapy.
Join Dr. Santa Maria as he discusses his current project exploring the use of chemotherapy combined with immunotherapy in patients with stage 2 and 3 triple-negative breast cancer. Learn how early PET scan changes are being used to identify patients who achieve a complete pathologic response earlier in the treatment process.
Dr. Asselah and Dr. Park discuss the impact of microenvironment interactions on tumor growth, treatment resistance, and potential therapeutic strategies with a focus on bridging basic to clinical research.
HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of ECOG-ACRIN 4112
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor
Loco-regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304.
Precocious modulation of metabolic and immunological parameters predicts tumor response to fasting-mimicking diet plus chemotherapy in patients with early stage TNBC
Dr. Nagi S. El Saghir, Director at NKBCI in Beirut, highlights six key abstracts from SABCS 2024. He shares insights on the rich multidisciplinary data presented this year, spanning innovations in breast cancer research and treatment.
Dr. Antonio Wolff shares expert commentary on SABCS 2024 highlights, including the practice-changing PATINA study, DCIS data, the COMET study, and the FDA's discussion on the importance of ovarian toxicity monitoring during clinical trials.
Prof. Amelie Ramirez discusses the importance of advancing research in prevention and treatment adherence for underserved Hispanic populations. She emphasizes clinical trial access and tailored treatments to combat breast cancer, a leading cause of death in this community.
Dr. Rita Sakr, Head of Breast Surgery at Emirates Hospital Dubai, discusses breast cancer survivors’ perspectives on de-escalation treatments in the Arab world and emphasizes the importance of education and raising awareness on de-escalation protocols.
Dr. Aydah AlAwadhi from the UAE shares insights on obesity's impact on breast cancer prevention, risk reduction, and prognosis, with key takeaways from Dr. H. Pan's (EBCTCG) presentation. She emphasizes the critical need for education and strategies to combat obesity in breast cancer patients.
Barbara Segarra-Vazquez, patient advocate and 2x breast cancer survivor, highlights drug optimization at SABCS 2024, emphasizing initiatives like Project Optimus and the importance of flexible dosing to enhance patients’ quality of life.
Prof. Amelie Ramirez reflects on SABCS 2024, highlighting advances from prevention to survivorship, the vital role of patient advocates in guiding research, and how new discoveries are improving the lives of breast cancer survivors.
Prof. Rebecca Dent discusses defining TNBC and shares updates from the KEYNOTE-522 study on neoadjuvant pembrolizumab for high-risk, early-stage TNBC. A detailed review of the progress and insights shaping TNBC management today.
Dr. Saima Hassan, Surgical Oncologist at the CHUM in Montreal and co-author of the B-59/GeparDouze study, emphasizes Quebec's role, contributing 17% of patients. She discusses the study's findings, its implications, and the need for further biomarker exploration.
Dr. Paolo Tarantino reviews two practice-changing trials presented at SABCS, EMBER-3 and PATINA. He discusses his own presentation on real-world data and innovative biomarkers for optimizing ADC use in breast oncology.
Dr. Joseph Gligorov discusses the pivotal PATINA trial results, emphasizing its significance as one of the most important data sets presented at SABCS 2024, with implications for advancing treatment in metastatic breast cancer.
On SABCS 2024's final day, Dr. Jean-Pierre Ayoub discusses three key abstracts, including NSABP B-59/GBG-96-GeparDouze on immunotherapy in TNBC and a subgroup analysis of TAILORx exploring chemotherapy variations. Valuable insights shared!
Dr. Jean-Pierre Ayoub discusses the evolving field of ADCs in Canada, comments on additional analysis from DESTINY-Breast06 by Dr. Aditya Bardia, and explores the expanding indications for trastuzumab deruxtecan (T-DXd).
Dr. Lisa Carey highlights the practice-changing PATINA trial, a mature study addressing the critical question of whether CDK4/6 inhibitors improve outcomes when added to antiestrogen and anti-HER2 therapies in first-line treatment of metastatic HR+/HER2+ breast cancer.
Dr. Xiaofu Zhu provides key takeaways from important abstracts at SABCS, including the EMBER-3 study, the exciting phase 2 SOLTI VALENTINE study, and highlights from several de-escalation studies.
Dr. Mitchell Elliott presents his spotlight poster on Day 3, evaluating the Pathlight Assay, a new ultra-sensitive ctDNA assay, in the early breast cancer setting. Discover the potential of this innovative diagnostic tool.
Dr. Jean-Pierre Ayoub shares insights on the DESTINY-Breast12 trial, highlighting the reassuring effects of T-DXd on quality of life and neurological function in HER2+ metastatic breast cancer patients, with or without brain metastases.
On Day 3, Dr. Stephanie Wong discussed the exciting results of the INSEMA trial, the second study showing that sentinel lymph node biopsy can be successfully omitted. We're eagerly awaiting further details to see if this approach can be widely implemented in practice.
Day 3 of SABCS 2024 reviewed by Drs. Sideris, Ayoub, and guest Dr. Ipshita Prakash, covering results from EUROPA, COMET, INSEMA, and PATINA trials. Key themes: de-escalation in treatment and a patient-centered care approach.
Dr. Kevin Kalinsky explores the impact of omitting axillary staging on adjuvant therapy in ER+ breast cancer. From SABCS' clinical controversy session, discover 4 key insights on systemic therapy implications.
Join Dr. Aditya Bardia as he explores the efficacy and safety of trastuzumab deruxtecan (T-DXd) vs. physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy in the latest DESTINY-Breast06 analysis.
Drs Lucas Sideris, Jean-Pierre Ayoub, and guest Cristiano Ferrario discuss Day 2 highlights including metastatic and early breast cancer updates, PADMA and EMBER-3 results, PRO B study insights, OlympiA follow-up, and what to expect on Day 3
Dr. Jane Meisel discusses key Day 2 updates from SABCS, including Dr. Matteo Lambertini's study on risk-reducing surgeries and survival in young BRCA carriers and the OlympiA Phase 3 10-year follow-up. These findings underscore advances and the importance of BRCA testing in early breast cancer.
Dr. Marie-France Jilderda discusses findings on the Adjusted Breast Cancer Index Model, exploring its role in identifying HR+ breast cancer patients at minimal 10-year distant recurrence risk and the key rationale behind this critical investigation.
Join Dr. Asselah and Dr. Sidéris as they review Day 1 of SABCS 2024, discussing late-breaking abstracts, key updates, and whether this year's findings could bring practice-changing advancements in breast cancer care.
Dr. Edith A. Perez, Professor Emeritus at Mayo Clinic, Chief Scientific Officer at oncoXchange, and an internationally recognized translational researcher and cancer specialist, previews SABCS 2024. She shares insights on the most anticipated abstracts and studies, highlighting exciting and potentially practice-changing results that could shape the future of breast cancer care.
Dr. Tarek Hijal provides key insights from Day 3 of ESMO 2024, focusing on the latest developments in hypofractionated radiotherapy for breast cancer. He discusses significant findings from the Phase III HypoG-01 trial, led by Dr. Sofia Rivera from Gustave Roussy, France. Dr. Hijal explores how these results are poised to impact breast cancer treatment, particularly in optimizing radiotherapy approaches for better patient outcomes.
Watch as Prof. Sibylle Loibl, PI of the PENELOPE-B trial, presents the final overall survival and subgroup analyses for lobular breast cancer patients at ESMO 2024. Gain a detailed overview of the study's key findings and implications.
Dr. Jamil Asselah, along with guests Dr. Kim Ma and Dr. Paolo Tarantino, discuss the morning sessions focused on metastatic and early breast cancer. The panel recaps significant data including insights from the DETECT V trial, KEYNOTE 522, DESTINY-Breast12, and updates from the Natalee trial.
Dr. Jean-Philippe Spano provides a brief history of ESMO's origins and its remarkable growth over the years. He reviews the latest data presented, with a special focus on contributions from his French colleagues and key international studies that have shaped clinical practice in breast cancer oncology.
Dr. Cristina Saura highlights three key messages from the ESMO 2024 meeting, focusing on significant advancements in breast cancer research. First, the results of the DESTINY-Breast12 trial showcased new treatment options for advanced breast cancer. Second, the ICARUS-BREAST01 study provided further insights into innovative therapeutic approaches. Lastly, she emphasized two groundbreaking international studies that confirmed breastfeeding after breast cancer treatment does not increase the risk of recurrence or new cancers, marking an important step for young survivors seeking safe breastfeeding options.
In this video,Dr. Amy Abernethy highlights the transformative potential of AI in oncology and stresses the need for safety and efficacy in patient care. She outlines three key trends essential for scaling AI in the field.
In this video, Dr. Erika Hamilton highlights the latest data on trastuzumab and HER2 testing presented at ESMO 2024. She provides valuable insights into recent advancements and their implications for treatment strategies in HER2-positive cancers.
In this DailyRECAP for September 15th, Dr. Jamil Asselah returns for a second overview of the day’s breast cancer sessions from ESMO 2024, joined by Dr. Rami Younan and Dr. Kim Ma. They focus on key insights from the Presidential Symposium and practice-changing trials.
Dr. Barbara Pistilli, Head of the Breast Pathology Committee at Gustave Roussy, presents the promising results of the Phase II ICARUS-BREAST01 trial at ESMO 2024.
Dr. Peter Schmid presents the long-awaited overall survival data for Pembrolizumab in early-stage triple-negative breast cancer. His insights provide a crucial update on the impact of this therapy, highlighting significant advancements in treatment outcomes.
Dr. Javier Cortés, Head of the International Breast Cancer Center in Barcelona, Spain, reviews key insights from the recent ASCO meeting, focusing on the PEARLY trial, A-BRAVE, and I-SPY 2.2 abstracts.
Dr. Erika P. Hamilton shares the findings that bring fantastic news for patients with HER2+ breast cancer, showing an impressive improvement in survival by approximately 10 months.
Explore the findings of the PALMARES-2 study with Dr. Claudio Vernieri, offering crucial real-world insights into the efficacy of CDK4/6 inhibitors. Learn how these insights aid clinicians and patients in making informed treatment decisions for specific clinical settings.
Dr. Dominici Chairs ASCO’s "Breast Cancer Local/Regional/Adjuvant" therapy session where 9 abstracts covered a number of different topics, three of which look at some interesting additions to standard therapy.
Dr. Shaheena Dawood shares her excitement about the wealth of information related to patients with breast cancer and how this data will impact clinical practice. In particular, she highlights three crucial pieces of information from ASCO and reviews data from the DESTINY-Breast06 Update, post MONARCH study and updated analysis from the innovaTV207 trial.
Dr. Maryellen Giger discusses the exciting developments in artificial intelligence (AI) applied to breast cancer imaging. From risk assessment to early detection, diagnosis, prognosis, and treatment response, AI is making significant strides
Join Dr. Stephanie Wong at ASCO as she presents data on PARP inhibitor eligibility in women with newly diagnosed invasive breast cancer. This research is part of the GREAT AGATA Study, a universal genetic testing initiative aimed at improving patient outcomes.
Dr. Judy-Anne Williams Chapman, PhD, emphasizes her four decades of work on the critical topic of estrogen and progesterone receptors. She proposes an adjunctive statistical standardization of quantitated ER and PgR to enhance inter-laboratory comparability of biomarker results and improve the therapeutic management of breast cancer.
Join Dr. Jamil Asselah and Dr. Kim Ma, along with Dr. Véronique Diéras, as they review the day's highlights with a special focus on the positive findings from the DESTINY-Breast06 trial. They will discuss how these results are set to impact clinical practice, particularly for patients with HER2-ultralow breast cancer, and delve into all aspects of T-DXd in treatment strategies.
Join Dr. Jane Lowe Meisel as she presents the first results from the I-SPY2.2 trial at ASCO. This study explores the use of datopotamab deruxtecan as part of neoadjuvant therapy for high-risk, HER2-negative early-stage breast cancer.
Join Dr. Matthew P. Goetz as he discusses the open-label, randomized, multicenter phase 3 ELAINE 3 study. This research investigates the efficacy and safety of lasofoxifene combined with abemaciclib for treating ER+/HER2- locally advanced or metastatic breast cancer with an ESR1 mutation. Discover the potential impact of these findings on patient care and treatment options.
Join Dr. Jean-Pierre Ayoub as he reviews important results from the DESTINY-Breast06 trial. Learn how Trastuzumab Deruxtecan significantly improves progression-free survival in breast cancer patients previously treated with endocrine therapy. Discover the potential implications of these findings for patient care and treatment strategies.
Join Dr. Nagi S. El Saghir as he discusses new studies presented at ASCO 2024. He highlights recent studies on the sequencing of CDK4/6 inhibitors and endocrine therapy in patients with advanced breast cancer.
Join Dr. Mark Basik as he presents the results of the TRICIA study, conducted across cancer centers and hospitals in Quebec and Ontario. Learn about the significant findings and the plans to initiate a clinical trial in the coming years, with the goal of advancing treatment options for this challenging type of cancer.
Join Drs. Asselah and Ma as they review the key takeaways from Day 1 of ASCO. They delve into hormone-positive disease, discuss notable abstracts, and provide insights on the Flex trial registry. Hear about Dr. Grace Choong’s research from Mayo Clinic on endocrine therapy for ER-low breast cancer patients. Stay tuned for what to expect in the days ahead at the conference.
Join Dr. Pier Franco Conte as he discusses the A-BRAVE trial, a Phase III randomized study exploring the use of avelumab in early triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy or those at high risk following primary surgery and adjuvant chemotherapy.
Join Dr. Santa Maria as he discusses his current project exploring the use of chemotherapy combined with immunotherapy in patients with stage 2 and 3 triple-negative breast cancer. Learn how early PET scan changes are being used to identify patients who achieve a complete pathologic response earlier in the treatment process.
HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of ECOG-ACRIN 4112
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor
Loco-regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304.
Precocious modulation of metabolic and immunological parameters predicts tumor response to fasting-mimicking diet plus chemotherapy in patients with early stage TNBC
